Studies of Selective Serotonin Reuptake Inhibitors (SSRIs) for major depression

A dataset from a systematic review examining the efficacy of different doses of SSRI antidepressant drugs and placebo (Furukawa et al. 2019) . The response to treatment is defined as a 50% reduction in depressive symptoms after 8 weeks (4-12 week range) follow-up. The dataset includes 60 RCTs comparing 5 different SSRIs with placebo.

ssri

Format

A data frame in long format (one row per arm and study), with 145 rows and 8 variables:

  • studyID Study identifiers

  • bias Risk of bias evaluated on 6 domains

  • age Mean participant age

  • weeks Duration of study follow-up

  • agent Character data indicating the agent to which participants were randomised

  • dose Numeric data indicating the dose to which participants were randomised in mg

  • n Numeric data indicating the number of participants randomised

  • r Numeric data indicating the number of participants who achieved >50% improvement in depression symptoms

References

Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G (2019). “Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.” Lancet Psychiatry, 6, 601-609.